Navigation Links
Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
Date:9/6/2007

- Trial to Assess Safety and Dose-Sparing Capability of Iomai Adjuvant

Patch -

GAITHERSBURG, Md., Sept. 6 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that it has begun dosing in a Phase 1/2 study that will assess the safety and dose-sparing capability of the company's immunostimulant patch when used in combination with an injected H5N1 influenza vaccine.

The Iomai patch, which contains a powerful immune-stimulating adjuvant, is used in conjunction with an injected influenza vaccine and may generate an immune response with small amounts of vaccine antigen. If successful, Iomai's approach may expand the pandemic influenza vaccine supply in the event of an influenza pandemic. This clinical trial is funded through an advanced development contract from the U.S. Department of Health and Human Services.

"This is the first human trial of the Iomai immunostimulant patch for use with a pandemic-like influenza vaccine, and the results of this study will give us crucial information about the ability of the patch to extend the vaccine supply in the event of a pandemic," said Stanley C. Erck, president and chief executive officer of Iomai. "Our patch is designed to solve the pressing problem of inadequate pandemic vaccine stocks, and we believe the results of this trial will validate our unique and flexible dose-sparing approach."

The study will enroll as many as 500 subjects, who will receive either a placebo injection or one of three dosages of pandemic influenza vaccine. Patients will receive a booster shot of placebo or vaccine 21 days later. Of these patients, approximately one-third will receive no immunostimulant patch, one-third will
'/>"/>

SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  ConvaTec today announced that it will report its 2013 first quarter ... CEO, and Ed Borkowski , CFO, will host an ... To participate in the conference call within the U.S. and ... in the conference call outside the U.S. and Canada ... Participants should dial in 10 minutes prior to the start ...
(Date:5/17/2013)... Puerto Rico , May 17, 2013 /PRNewswire/ ... western Puerto Rico , Caribbean Imaging and ... has improved its radiation therapy capabilities with the acquisition of ... Puerto Rico . Versa HD offers clinicians the versatility ... tumors throughout the body, while also enabling treatment of highly ...
(Date:5/17/2013)... Conn. , May 17, 2013  Boehringer ... in respiratory disease at the American Thoracic Society ... PA , May 17 – 22. ... product approved for the treatment of chronic obstructive ... powder)], as well as investigational compounds for asthma, ...
Breaking Medicine Technology:Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... Valeant Pharmaceuticals International, Inc. (NYSE: ... Valeant has agreed to acquire certain assets from ... focused on skincare products, for approximately $64 million ... revenue targets.  University Medical,s main brand is AcneFree, ...
... 3, 2012 Dutch Medical Brands receives ... Instead of traditional treatment with antibiotics, bladder and urinary ... known side effects. Dutch company Medical Brands has obtained ... Cranberry-Active capsule, making it the first and only cranberry-based ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2Cranberry Capsule Proven to Cure Bladder Infection 2
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 As ... courts throughout the country, Bernstein Liebhard LLP notes that ... patients often suffer tissue damage before they experience any ... according to Science Daily will appear in the Journal ... recipients underwent MRI screens of their hips. The ...
(Date:5/18/2013)... May 18, 2013 The “Sleep Apnea ... Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal ... to 2017” analyzes and studies the major market drivers, ... Rest of the World. , Browse , ... 16 Figures , 318 pagesand ...
(Date:5/18/2013)... The Ayurvedic practitioner program will be offered in ... Program is available in Mexico via Live Internet or ... practiced for over 5,000 years. In Ayurvedic medicine ( ... when an individual lives in harmony with their environment, ... aims to heal an individual in all levels (physically, ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Losing weight remains ... But among the horde of new weight loss products available ... talked about. Recent studies about this newest weight loss supplement ... ideal body shape. , Garcinia Cambogia is a sub-tropical fruit ... tamarind. Eating the fruit can suppress a person’s appetite, while ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Wake Forest University School of Medicine has reported in ... to the aorta which may occur due to bypass ... heart which may lead to cognitive loss and the ... to the aorta reduces development of cognitive defects. ...
... wristwatch invented by South Africa's Gervan Lubbe which can detect ... hazard. They have warned that the device may contribute towards ... also expressed doubts if the watch can really perform functions ... a potential public health threat as opposed to a boon ...
... four Marlboro smokers for hi-tech screenings aimed at the early detection ... pay for spiral CT scans which is estimated at ?300. //If ... save several thousand lives as a result of early detection. The ... smoking. ,A class action status is sought by ...
... International study conducted by the University of New South ... the HIV treatment can be life threatening and resulted ... because //they identified that the patients who took a ... progression of the disease, compared with those who took ...
... teenage smokers in Alberta in 2005, when in comparison to 2004. ... are being blamed for this by anti-smoking campaigners. The young adult ... the Alberta Alcohol and Drug Abuse Commission for this state of ... of Alberta who belong to the age group of 15 years ...
... the Health Minister on the prescription issue. Under this nurses ... move has been widely criticized, but the BMA's GP committee ... statement of the Health Minister on the introduction of nurse ... who should be able to spend more time with those ...
Cached Medicine News:Health News:Breaks In The HIV Treatment Resulted In Devastating Results. 2
... The MultiBlot tray is specifically designed ... commonly used 10.16 x 13.34cm dot blot ... exterior dimensions as a standard microplate for ... and accepts commercially available dot blot membranes ...
... offers rapid and effective transfers over ... blotting area. Designed for use with ... used with the PROTEAN Plus Dodeca ... provides uniform transfers in as little ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
... regulator. The Model 785 vacuum blotter ... from an agarose gel onto a nylon ... min for transfer, the nucleic acid samples ... to a membrane, and the hybridization reaction ...
Medicine Products: